PT-141: reading the RECONNECT trials in context

Evidence discussed: Two randomized phase 3 human trials.

What the researchers studied

Two placebo-controlled trials studied bremelanotide in premenopausal women with hypoactive sexual desire disorder. Researchers reported improvements in desire scores and distress associated with low desire during the treatment period. [1]

How to interpret the result

Nausea, flushing and headache occurred more frequently with bremelanotide. Findings concern a defined population and clinical formulation, not a universal effect on sexual function or a test of research stock.

What readers can take from it

The diagnosis and patient-reported endpoints matter. A significant questionnaire change within a trial is not a guaranteed outcome for every person or formulation.

This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.

Source

[1] Kingsberg et al., RECONNECT bremelanotide trials (2019). PMID: 31599840. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.